ATE518540T1 - Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung - Google Patents

Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung

Info

Publication number
ATE518540T1
ATE518540T1 AT00959244T AT00959244T ATE518540T1 AT E518540 T1 ATE518540 T1 AT E518540T1 AT 00959244 T AT00959244 T AT 00959244T AT 00959244 T AT00959244 T AT 00959244T AT E518540 T1 ATE518540 T1 AT E518540T1
Authority
AT
Austria
Prior art keywords
lactam compound
composition containing
containing beta
neurotherapeutic
treatment
Prior art date
Application number
AT00959244T
Other languages
English (en)
Inventor
Gary Koppel
Original Assignee
Revaax Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revaax Pharmaceuticals Llc filed Critical Revaax Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE518540T1 publication Critical patent/ATE518540T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00959244T 1999-08-16 2000-08-16 Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung ATE518540T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14911599P 1999-08-16 1999-08-16
US17245299P 1999-12-17 1999-12-17
US17657000P 2000-01-18 2000-01-18
US19453400P 2000-04-04 2000-04-04
PCT/US2000/022450 WO2001012184A1 (en) 1999-08-16 2000-08-16 Neurotherapeutic composition and method

Publications (1)

Publication Number Publication Date
ATE518540T1 true ATE518540T1 (de) 2011-08-15

Family

ID=27495857

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00959244T ATE518540T1 (de) 1999-08-16 2000-08-16 Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
AT00955580T ATE319447T1 (de) 1999-08-16 2000-08-16 Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00955580T ATE319447T1 (de) 1999-08-16 2000-08-16 Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen

Country Status (14)

Country Link
US (5) US6627625B1 (de)
EP (3) EP1206261B1 (de)
JP (2) JP5049437B2 (de)
CN (1) CN1382047A (de)
AT (2) ATE518540T1 (de)
AU (2) AU781218B2 (de)
BR (1) BR0013366A (de)
CA (3) CA2383522C (de)
DE (1) DE60026538T2 (de)
DK (1) DK1206261T3 (de)
ES (1) ES2258980T3 (de)
MX (1) MXPA02001667A (de)
NZ (1) NZ517663A (de)
WO (2) WO2001012171A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
ATE518540T1 (de) * 1999-08-16 2011-08-15 Revaax Pharmaceuticals Llc Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
AU2001291499B2 (en) * 2000-09-29 2007-02-08 Nucor Corporation A method of producing steel
US20030013635A1 (en) * 2001-04-11 2003-01-16 Meyerhoff James L. Method for the treatment of depression by inhibition of NAALADase
CA2446853A1 (en) * 2001-05-15 2002-11-21 Psychogenics Inc. Systems and methods for monitoring behavior informatics
US7166626B2 (en) * 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
MXPA04003358A (es) * 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003061605A2 (en) * 2002-01-17 2003-07-31 R.E.D. Laboratories, N.V./S.A. Methods of treatment of chronic immune disease
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
EP1558231A4 (de) * 2002-10-03 2010-09-08 Cypress Bioscience Inc Dosiseskalation und geteilte tagesdosis von antidepressiva zurbehandlung von neurologischen erkrankungen
NZ540288A (en) * 2002-11-22 2009-06-26 Univ Johns Hopkins Target for therapy of cognitive impairment
AU2004214938B2 (en) * 2003-02-26 2008-11-06 Johns Hopkins University Glutamate transport modulatory compounds and methods
MXPA06002125A (es) * 2003-08-25 2006-05-31 Revaax Pharmaceuticals Llc Composiciones orales de cefazolin neuroterapeutico.
AU2004285473A1 (en) * 2003-10-21 2005-05-12 Johns Hopkins University Neuroprotection with beta-lactam compounds
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
ES2564187T3 (es) * 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
EP1910346B1 (de) 2005-07-19 2019-02-27 Azevan Pharmaceuticals, Inc. Beta-lactamyl-phenylalanin, -cystein und -serin als vasopressinantagonisten
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
CA2702257C (en) * 2007-10-09 2016-07-12 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
KR20100101574A (ko) 2007-10-26 2010-09-17 렉산 파마슈티컬스, 인코포레이티드 클라불란산의 제약 제제
US8101600B2 (en) * 2008-12-23 2012-01-24 Brookhaven Science Associates, Llc Method of treating depression
US20100261700A1 (en) * 2009-04-09 2010-10-14 Larry Sutton Beta-lactamase inhibitors
CN102413814A (zh) * 2009-04-29 2012-04-11 瑞恩药品公司 用于神经保护和治疗神经变性病症的克拉维酸类物质制剂
PL3351104T3 (pl) 2010-07-01 2021-06-14 Azevan Pharmaceuticals, Inc. Związki do stosowania w leczeniu okresowych zaburzeń wybuchowych
WO2013006808A2 (en) * 2011-07-06 2013-01-10 Rexahn Pharmaceuticals, Inc. Clavulanic acid for treatment of restless legs syndrome
US9744160B2 (en) * 2011-07-26 2017-08-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
EP2768503A1 (de) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmazeutische zusammensetzungen mit einem beta-lactam-antibiotikum, sulbactam beta-lactamase-inhibitor
HK1201466A1 (en) 2011-09-21 2015-09-04 干细胞医药有限公司 Beta-lactam compounds for treating diabetes
CN103906516A (zh) 2011-09-21 2014-07-02 干细胞医药有限公司 用于增强T细胞介导的免疫应答的β-内酰胺化合物
CA2879113C (en) 2012-07-22 2021-11-16 Indiana University Research And Technology Corporation Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9975905B2 (en) 2013-03-12 2018-05-22 Gladius Pharmaceuticals Corporation Derivatized 3-styryl-cephalosporins
DK2893929T3 (da) 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3043797B1 (de) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Behandlung von infektionen mit ceftolozan/tazobactam bei personen mit beeinträchtigter nierenfunktion
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
RU2696481C2 (ru) 2013-10-14 2019-08-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение акампросата для модулирования активации erk1/2 в животных моделях fxs и asd и людей с диагностированными fxs и asd
SG10202001065SA (en) 2014-03-28 2020-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
WO2017218697A1 (en) * 2016-06-17 2017-12-21 The Trustees Columbia University In The City Of New York Identification of compounds that target the rna-binding protein tia-1 an important regulator of stress vulnerability in both mice and humans
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
CN108522431A (zh) * 2018-04-03 2018-09-14 葛仟鸿 抗生素对果蝇记忆认知影响用测定方法
SG11202101255UA (en) 2018-08-09 2021-03-30 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2020263975A1 (en) * 2019-06-24 2020-12-30 Diverse Biotech, Inc. Beta-lactam-cannabinoid conjugate molecules
CN112843034B (zh) * 2019-11-26 2022-08-23 亚瑟瑞智科技管理顾问股份有限公司 包含克拉维酸与丙戊酸的组合物及其用途
WO2022102801A1 (ko) * 2020-11-10 2022-05-19 김현기 오배자 추출물 및 암피실린을 유효성분으로 포함하는 인지력 개선, 치매 및 과잉행동장애 예방 및 치료용 조성물
CN114767690B (zh) * 2022-06-22 2022-08-23 中国中医科学院中药研究所 头孢噻吩酸在制备抗抑郁药物中的应用
CN117144006B (zh) * 2023-08-18 2025-02-18 大连医科大学附属第二医院 Lactb基因及其在诊断前列腺癌中的应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508977A (en) * 1974-04-20 1978-04-26 Beecham Group Ltd Beta-lactam antibiotic from streptomyces clavuligerus
US4110165A (en) * 1974-04-20 1978-08-29 Beecham Group Limited Process for the production of clavulanic acid
CA1085392A (en) * 1976-03-25 1980-09-09 Masayuki Narisada Arylmalonamido-1-oxadethiacephalosporins
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4234579A (en) * 1977-06-07 1980-11-18 Pfizer Inc. Penicillanic acid 1,1-dioxides as β-lactamase inhibitors
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
US4268503A (en) 1978-09-14 1981-05-19 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4302503A (en) * 1978-05-17 1981-11-24 Libbey-Owens-Ford Company Architectural spandrel
US4349672A (en) * 1979-11-29 1982-09-14 Hoffmann-La Roche Inc. Cephalosporin derivatives
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
US4594247A (en) 1981-12-21 1986-06-10 Eli Lilly And Company Synergistic antibacterial compositions and method of treatment of infections caused by multiple antibiotic-resistant organisms
US4824850A (en) 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4900837A (en) 1982-05-18 1990-02-13 University Of Florida Brain-specific drug delivery of steroid sex hormones cleaved from pyridinium carboxylates and dihydro-pyridine carboxylate precursors
US5187158A (en) 1982-05-18 1993-02-16 University Of Florida Brain-specific drug delivery
US5008257A (en) 1982-05-18 1991-04-16 University Of Florida Brain-specific drug delivery
US4880921A (en) 1982-05-18 1989-11-14 University Of Florida Brain-specific drug delivery
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
JPS59104389A (ja) * 1982-12-06 1984-06-16 Shionogi & Co Ltd オキサセファム誘導体
JPS59225182A (ja) * 1983-03-25 1984-12-18 Yamanouchi Pharmaceut Co Ltd ２−アゼチジノン−４−カルボン酸の誘導体
US4628077A (en) 1983-12-16 1986-12-09 The Standard Oil Company Preparation of polyamide with catalyst comprising transition metal attached to a ligand which contains electron withdrawing groups
US5082853A (en) 1984-02-29 1992-01-21 Bodor Nicholas S Brain-specific analogues of centrally acting amines
US4933438A (en) 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US4771059A (en) 1984-02-29 1988-09-13 University Of Florida Brain-specific analogues of centrally acting amines
JPS62106015A (ja) * 1985-10-31 1987-05-16 Sumitomo Pharmaceut Co Ltd 抗痴呆薬
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5552543A (en) 1988-12-14 1996-09-03 Simon Fraser University Six-membered hetero "N" compounds
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5681812A (en) 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
GB9201639D0 (en) * 1992-01-25 1992-03-11 Smithkline Beecham Plc Pharmaceutical formulations
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
CA2151714C (en) * 1993-10-20 2005-10-11 Shogo Ito Mobile communications method
WO1995012601A1 (en) * 1993-11-06 1995-05-11 Taiho Pharmaceutical Co., Ltd. Crystalline penicillin derivative, and its production and use
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
DE19509697A1 (de) 1995-03-08 1996-09-12 Schering Ag Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5827537A (en) * 1995-05-04 1998-10-27 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9518917D0 (en) * 1995-09-15 1995-11-15 Smithkline Beecham Plc Compounds
GB9525697D0 (en) * 1995-12-15 1996-02-14 Pharmacia Spa Cephem derivatives
WO1997030707A1 (en) 1996-02-23 1997-08-28 Eli Lilly And Company NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
US5905076A (en) * 1996-04-10 1999-05-18 National Research Council Of Canada 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors
US5795877A (en) * 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6054444A (en) * 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
CA2264043A1 (en) * 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
ID18382A (id) * 1996-09-27 1998-04-02 Guilford Pharm Inc Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase
JP2002507189A (ja) 1997-01-23 2002-03-05 ナエジャ ファーマシューティカル インコーポレーティッド システイン・プロテアーゼ阻害剤としての置換アミノ二環式−β−ラクタムペナムおよびセファム誘導体
EP0994707A4 (de) * 1997-05-27 2001-11-14 Guilford Pharm Inc Inhibitoren der naaladase-enzym-aktivität
AU8140898A (en) * 1997-06-13 1998-12-30 Northwestern University Inhibitors of beta-lactamases and uses therefor
JP2001514375A (ja) 1997-08-22 2001-09-11 パーデュー・リサーチ・ファウンデーション 多重膜擬似親和力を利用する薬物の発見支援
AU2114199A (en) 1998-01-13 1999-08-02 Trustees Of The University Of Pennsylvania, The Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6177421B1 (en) * 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
AU7497000A (en) 1999-02-28 2000-11-14 Washington University Novel transduction molecules and methods for using same
MXPA02000246A (es) * 1999-07-06 2003-08-20 Methylgene Inc Inhibidores de °-lactamasa de sulfonamidometil fosfonato.
US6426342B2 (en) 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
ATE518540T1 (de) * 1999-08-16 2011-08-15 Revaax Pharmaceuticals Llc Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
US6489319B2 (en) 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
FR2811287B1 (fr) * 2000-07-04 2002-10-04 Look Cycle Int Pedale de cycle a positionnement reglable perfectionne
WO2002064147A1 (en) 2001-02-13 2002-08-22 Revaax Pharmaceuticals, Llc Antibiotic compositon and method
US7166626B2 (en) * 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
MXPA06002125A (es) * 2003-08-25 2006-05-31 Revaax Pharmaceuticals Llc Composiciones orales de cefazolin neuroterapeutico.
JP4792032B2 (ja) * 2004-08-13 2011-10-12 シェーリング−プラウ・リミテッド 抗生物質、トリアゾールおよびコルチコステロイドを含む薬学的処方物
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
CN102413814A (zh) * 2009-04-29 2012-04-11 瑞恩药品公司 用于神经保护和治疗神经变性病症的克拉维酸类物质制剂

Also Published As

Publication number Publication date
AU781218B2 (en) 2005-05-12
NZ517663A (en) 2006-02-24
JP2003506490A (ja) 2003-02-18
EP1212055A1 (de) 2002-06-12
EP1206261B1 (de) 2006-03-08
US20080200447A1 (en) 2008-08-21
DE60026538D1 (de) 2006-05-04
CA2383522C (en) 2011-12-06
WO2001012171A2 (en) 2001-02-22
AU6776300A (en) 2001-03-13
CN1382047A (zh) 2002-11-27
ATE319447T1 (de) 2006-03-15
CA2746824A1 (en) 2001-01-22
BR0013366A (pt) 2002-07-23
WO2001012184A1 (en) 2001-02-22
CA2383522A1 (en) 2001-01-22
EP1206261A2 (de) 2002-05-22
US7842683B2 (en) 2010-11-30
JP2011201899A (ja) 2011-10-13
US20040229857A1 (en) 2004-11-18
US6610681B1 (en) 2003-08-26
EP1212055B1 (de) 2011-08-03
EP1212055A4 (de) 2005-09-07
US20040014739A1 (en) 2004-01-22
DK1206261T3 (da) 2006-07-03
EP2305251A2 (de) 2011-04-06
JP5049437B2 (ja) 2012-10-17
EP2305251A3 (de) 2011-05-18
DE60026538T2 (de) 2007-02-01
MXPA02001667A (es) 2003-07-14
WO2001012171A3 (en) 2002-01-17
ES2258980T3 (es) 2006-09-16
AU7059800A (en) 2001-03-13
CA2380820A1 (en) 2001-02-22
US6627625B1 (en) 2003-09-30

Similar Documents

Publication Publication Date Title
ATE518540T1 (de) Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU7031500A (en) Therapeutic quinazoline compounds
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
TR200001279T2 (tr) Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
GB0005251D0 (en) Therapeutic compounds
TR199901604T2 (xx) Tedavide yararl� kinolin ve kinazolin bile�ikleri.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MY119375A (en) Treatment of tinnitus using neuroprotective agents
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
MXPA05012955A (es) Composiciones farmaceuticas de atorvastatina.
EP1743656A3 (de) pharmazeutische Kombination zur Behandlung von benigner Prostatahyperplasie oder zur Langzeitvorbeugung von akuter Harnretention
EP1109560A4 (de) Als inhibitoren der aicarftnützliche verbindungen
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
HUP0003589A2 (hu) Prosztatarák és jóindulatú prostatohyperplasia gyógykezelése vagy megelőzése szelektív ösztrogénreceptor-modulátorokkal
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties